CY1109865T1 - Συνθεσεις βαλσαρτανης - Google Patents

Συνθεσεις βαλσαρτανης

Info

Publication number
CY1109865T1
CY1109865T1 CY20101100204T CY101100204T CY1109865T1 CY 1109865 T1 CY1109865 T1 CY 1109865T1 CY 20101100204 T CY20101100204 T CY 20101100204T CY 101100204 T CY101100204 T CY 101100204T CY 1109865 T1 CY1109865 T1 CY 1109865T1
Authority
CY
Cyprus
Prior art keywords
valsartan
compositions
valsartan compositions
active agent
microcrystalline cellulose
Prior art date
Application number
CY20101100204T
Other languages
English (en)
Inventor
Ümit Cifter
Ali Türkyilmaz
Hasan Ali Turp
Original Assignee
Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38982518&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1109865(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi filed Critical Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi
Publication of CY1109865T1 publication Critical patent/CY1109865T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε μια νέα φαρμακευτική σύνθεση στη μορφή ενός δισκίου που αποτελείται από βαλσαρτάνη ως μια δραστική ουσία, προζελατοποιημένο άμυλο, μικροκρυσταλλική κυτταρίνη.
CY20101100204T 2007-05-24 2010-03-01 Συνθεσεις βαλσαρτανης CY1109865T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2007/03568A TR200703568A1 (tr) 2007-05-24 2007-05-24 Valsartan formülasyonları
EP08104077A EP1994926B9 (en) 2007-05-24 2008-05-23 Valsartan formulations

Publications (1)

Publication Number Publication Date
CY1109865T1 true CY1109865T1 (el) 2014-09-10

Family

ID=38982518

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100204T CY1109865T1 (el) 2007-05-24 2010-03-01 Συνθεσεις βαλσαρτανης

Country Status (12)

Country Link
US (1) US20080293789A1 (el)
EP (1) EP1994926B9 (el)
AT (1) ATE451097T1 (el)
CY (1) CY1109865T1 (el)
DE (1) DE602008000367D1 (el)
DK (1) DK1994926T3 (el)
ES (1) ES2337848T3 (el)
HR (1) HRP20100120T1 (el)
PL (1) PL1994926T3 (el)
PT (1) PT1994926E (el)
SI (1) SI1994926T1 (el)
TR (1) TR200703568A1 (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2405899A2 (en) * 2009-03-11 2012-01-18 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Valsartan formulations
TR201005419A2 (tr) * 2010-07-05 2012-01-23 Bi̇lgi̇ç Mahmut Valsartan içeren farmasötik bileşim.
EP2990029A1 (en) * 2014-08-29 2016-03-02 Sandoz Ag Pharmaceutical compositions comprising Canagliflozin
CN105769788A (zh) * 2016-03-11 2016-07-20 江苏中邦制药有限公司 一种缬沙坦片剂及制备方法
CN105816419A (zh) * 2016-05-26 2016-08-03 陈欣怡 一种包含缬沙坦的药物组合物
CN112826806A (zh) * 2021-01-20 2021-05-25 海南皇隆制药股份有限公司 一种缬沙坦片制备方法和缬沙坦片
CN112807286A (zh) * 2021-01-20 2021-05-18 海南皇隆制药股份有限公司 一种缬沙坦分散片制备方法和缬沙坦分散片

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK117793A3 (en) 1991-04-29 1994-05-11 Merck & Co Inc Optimized tablet formulation
DE4408497A1 (de) 1994-03-14 1995-09-21 Thomae Gmbh Dr K Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO1995024901A1 (en) 1994-03-17 1995-09-21 Ciba-Geigy Ag Treatment of diabetic nephropathy with valsartan
TW442301B (en) 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
ATE354364T1 (de) 1998-12-23 2007-03-15 Novartis Pharma Gmbh Verwendung von at-1 rezeptorantagonisten oder at- 2 rezeptormodulatoren zur behandlung von erkrankungen, die mit einer erhöhung an at-1 oder at-2 rezeptoren verbunden sind
US20020132839A1 (en) * 2000-06-22 2002-09-19 Ganter Sabina Maria Tablet formulations comprising valsartan
US9173847B2 (en) * 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
EP1680095A2 (en) 2003-11-03 2006-07-19 Zentiva, a.s. Valsartan containing formulation
EA012392B1 (ru) * 2004-12-24 2009-10-30 Крка, Д.Д. Ново Место Твердая фармацевтическая композиция, содержащая валсартан
WO2007026261A2 (en) * 2005-05-18 2007-03-08 Combino Pharm, S.L. Formulations containing losartan and/or its salts
GT200600371A (es) * 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
JP2009513622A (ja) * 2005-10-27 2009-04-02 ルピン・リミテッド ロサルタンの医薬製剤
WO2007049291A1 (en) * 2005-10-27 2007-05-03 Lupin Limited Novel solid dosage forms of valsartan and rochlorothiazide
US20080227836A1 (en) * 2005-10-31 2008-09-18 Lupin Ltd Stable Solid Oral Dosage Forms of Valsartan

Also Published As

Publication number Publication date
DK1994926T3 (da) 2010-04-26
PT1994926E (pt) 2010-03-16
EP1994926A1 (en) 2008-11-26
SI1994926T1 (sl) 2010-04-30
EP1994926B9 (en) 2010-05-19
ES2337848T3 (es) 2010-04-29
ATE451097T1 (de) 2009-12-15
US20080293789A1 (en) 2008-11-27
EP1994926B1 (en) 2009-12-09
DE602008000367D1 (de) 2010-01-21
HRP20100120T1 (hr) 2010-04-30
PL1994926T3 (pl) 2010-05-31
TR200703568A1 (tr) 2008-07-21

Similar Documents

Publication Publication Date Title
NO20083630L (no) Nye pyridinderivater
NO20091395L (no) Nye tiofenderivater
CY1109865T1 (el) Συνθεσεις βαλσαρτανης
BRPI0820997A2 (pt) Comprimidos de desintegração oral compreendendo difenidramina.
MX2010005889A (es) Derivados de tiofeno como agonistas de s1p1/edg1.
NO20082793L (no) Nye tiofenderivater
MY154909A (en) Novel thiophene derivatives
NO20090295L (no) Substituerte heteroarylderivater
MY153921A (en) Aminopyrazole derivatives
DK3984528T3 (da) Farmaceutiske sammensætninger, som omfatter nilotinib
NO20075298L (no) Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists
TNSN08326A1 (en) Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
MX2011012739A (es) Derivados fluorados de aminotriazol.
DK3045164T3 (da) Vandige farmaceutiske sammensætninger, der indeholder borat-polyol-komplekser
DK2254549T3 (da) Vandige farmaceutiske sammensætninger, indeholdende borat-polyol-komplekser
SI2242740T1 (sl) SF5-derivati kot PAR1 inhibitorji, njihova priprava in uporaba kot zdravila
EA201190320A1 (ru) Гетероциклические сульфонамиды, их применения и фармацевтические композиции
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
UA107671C2 (en) N1-substityted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives
UY31128A1 (es) Formulacion de nevirapina de liberacion prolongada
MA32461B1 (fr) Dronedarone pour la prevention de cardioversion
ATE533477T1 (de) Pharmazeutische zusammensetzungen enthaltend irbesartan
EA200801678A1 (ru) Применение производных триазина для производства лекарственного средства, обладающего заживляющим или ангиогенным эффектом
CY1110787T1 (el) Νεα μορφινικα παραγωγα
EA200870157A1 (ru) Производные 2-карбамид-4-фенилтиазола, их получение и их применение в терапии